Many experts have been predicting some big mergers and acquisitions in the psychedelic industry. Well, it looks like they were spot on. This week has...
The psychedelic industry is changing and growing rapidly. Psychedelic medicines are being catapulted into the mainstream, and these top 10 psychedelic...
Atai Life Sciences Q2 financial results were released recently, alongside an update on the company’s pipeline progression. So, we figured it would be...
COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time. The post COMPASS...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed First...
MN gov invites Iowans to try legal marijuana; AMA study: cannabis seen as safer than cigs; MI sales; Congressional bill targets Prince Harry drug use Subscribe to...
Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound. The post Christian Angermayer...
Atai Life Sciences (NASDAQ: ATAI) reported its second quarter 2023 financial results and provided corporate updates. At this time Atai has no revenue to...
Atai noted it was exploring strategic options for the study. The post Atai May Step Away from Ketamine Study After Releasing Positive Results appeared...
Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The post atai Life...